FAQ: Quantum BioPharma's Response to Law Firm Allegations and Company Overview
Summary
Quantum BioPharma has formally rejected what it describes as vague and unsubstantiated claims by The Schall Law Firm and DJS Law Group regarding alleged securities law violations. The company is reviewing the conduct of both firms and will take appropriate action to address what it believes is a deliberate attempt to harm its reputation.
What is the main topic of this announcement?
Quantum BioPharma has issued a formal response rejecting what it describes as vague and unsubstantiated claims made by The Schall Law Firm and DJS Law Group regarding alleged securities law violations, stating the announcements lack factual detail and appear intended to mislead investors.
Why is Quantum BioPharma responding to these law firm announcements?
The company believes the claims are unsubstantiated and appear intended to mislead investors and provoke unwarranted concern, potentially harming its reputation in the investment community.
What actions is Quantum BioPharma taking regarding these claims?
Quantum BioPharma stated it is reviewing the conduct of both law firms and their principals and will take appropriate action to address what it believes is a deliberate attempt to harm its reputation.
What is Quantum BioPharma’s primary business focus?
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.
What is Quantum BioPharma’s lead compound and what does it treat?
Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
What is unbuzzd(TM) and what is Quantum BioPharma’s involvement with it?
Quantum BioPharma invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining ownership of 20.11% (as of March 31, 2025) and receiving royalty payments of 7% of sales until payments total $250 million, then 3% in perpetuity, while keeping 100% rights for pharmaceutical and medical uses.
Where can investors find more information about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM, and the full press release can be viewed at https://ibn.fm/TsBbx.
What other business activities does Quantum BioPharma engage in?
Through its wholly owned subsidiary FSD Strategic Investments Inc., Quantum BioPharma maintains a portfolio of strategic investments representing loans secured by residential or commercial property.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 251925